<DOC>
	<DOCNO>NCT01909492</DOCNO>
	<brief_summary>This study evaluate relaxin ( RLX ) level patient multiple sclerosis .</brief_summary>
	<brief_title>Relaxin Multiple Sclerosis ( MS )</brief_title>
	<detailed_description>The goal study obtain baseline information serum cerebrospinal fluid ( CSF ) relaxin level patient MS , well study RXFP-1 receptor bind affinity RLX patient active clinically stable MS .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Methocarbamol</mesh_term>
	<criteria>Subjects suspect MS , clinical attack within last 12 week , least one gadoliniumenhancing lesion brain spinal cord MRI take within prior 4 week , receive immunomodulating immunosuppressant medication . Subjects clinically stable definite MS , evidence clinical relapse least past 12 week , gadolinium enhance lesion MRI prior 4 week . These subject fulfill Revised ( 2010 ) McDonald 's Criteria Diagnosis MS . Subjects without evidence inflammatory systemic inflammatory central nervous system disease , require CSF removal cause , treatment benign intracranial hypertension part procedure insertion intrathecal medication delivery system . Pregnancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>Relaxin</keyword>
</DOC>